Literature DB >> 30465948

Predictors of Venous Thromboembolism After Nonemergent Craniotomy: A Nationwide Readmission Database Analysis.

Ian A Buchanan1, Michelle Lin2, Daniel A Donoho3, Arati Patel2, Li Ding4, Arun P Amar5, Steven L Giannotta5, William J Mack5, Frank Attenello5.   

Abstract

BACKGROUND: Venous thromboembolism (VTE) is responsible for many hospital readmissions each year, particularly among postsurgical cohorts. Because early and indiscriminate VTE prophylaxis carries catastrophic consequences in postcraniotomy cohorts, identifying factors associated with a high risk for thromboembolic complications is important for guiding postoperative management.
OBJECTIVE: To determine VTE incidence in patients undergoing nonemergent craniotomy and to evaluate for factors that predict 30-day and 90-day readmission with VTE.
METHODS: The 2010-2014 cohorts of the Nationwide Readmissions Database were used to generate a large heterogeneous craniotomy sample.
RESULTS: There were 89,450 nonemergent craniotomies that met inclusion criteria. Within 30 days, 1513 patients (1.69%) were readmitted with VTE diagnoses; among them, 678 (44.8%) had a diagnosis of deep vein thrombosis alone, 450 (29.7%) had pulmonary embolism alone, and 385 (25.4%) had both. The corresponding 30-day deep vein thrombosis and pulmonary embolism incidences were 1.19% and 0.93%, respectively. In multivariate analysis, several factors were significantly associated with VTE readmission, namely, craniotomy for tumor, corticosteroids, advanced age, greater length of stay, and discharge to institutional care.
CONCLUSIONS: Craniotomies for tumor, corticosteroids, advanced age, prolonged length of stay, and discharge to institutional care are significant predictors of VTE readmission. The implication of steroids, coupled with their ubiquity in neurosurgery, makes them a potentially modifiable risk factor and a prime target for VTE reduction in craniotomy cohorts. Furthermore, the fact that dose is proportional to VTE risk in the literature suggests that careful consideration should be given toward decreasing regimens in situations in which use of a lower dose might prove equally sufficient.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adult cohort; Craniotomy; Deep vein thrombosis (DVT); Nationwide database; Pulmonary embolism (PE); Readmission; Venous thromboembolism (VTE)

Mesh:

Year:  2018        PMID: 30465948      PMCID: PMC6363858          DOI: 10.1016/j.wneu.2018.10.237

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  60 in total

1.  Cancer-associated thrombosis.

Authors:  Rodger L Bick
Journal:  N Engl J Med       Date:  2003-07-10       Impact factor: 91.245

Review 2.  Cancer and the prothrombotic state.

Authors:  Gregory Y H Lip; Bernard S P Chin; Andrew D Blann
Journal:  Lancet Oncol       Date:  2002-01       Impact factor: 41.316

3.  Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study.

Authors:  J A Heit; M D Silverstein; D N Mohr; T M Petterson; W M O'Fallon; L J Melton
Journal:  Arch Intern Med       Date:  2000-03-27

4.  Low-molecular-weight and unfractionated heparin for prevention of venous thromboembolism in neurosurgery: a meta-analysis.

Authors:  A Iorio; G Agnelli
Journal:  Arch Intern Med       Date:  2000 Aug 14-28

5.  Glucocorticoids and insulin promote plasminogen activator inhibitor 1 production by human adipose tissue.

Authors:  P E Morange; J Aubert; F Peiretti; H R Lijnen; P Vague; M Verdier; R Négrel; I Juhan-Vague; M C Alessi
Journal:  Diabetes       Date:  1999-04       Impact factor: 9.461

Review 6.  Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

Authors:  William H Geerts; Graham F Pineo; John A Heit; David Bergqvist; Michael R Lassen; Clifford W Colwell; Joel G Ray
Journal:  Chest       Date:  2004-09       Impact factor: 9.410

7.  Genetic and plasma markers of venous thromboembolism in patients with high grade glioma.

Authors:  Francesca L Sciacca; Emilio Ciusani; Antonio Silvani; Elena Corsini; Simona Frigerio; Simona Pogliani; Eugenio Parati; Danilo Croci; Amerigo Boiardi; Andrea Salmaggi
Journal:  Clin Cancer Res       Date:  2004-02-15       Impact factor: 12.531

8.  Postoperative venous thromboembolism and brain tumors: Part II. Hemostatic profile.

Authors:  R Sawaya; P Glas-Greenwalt
Journal:  J Neurooncol       Date:  1992-10       Impact factor: 4.130

Review 9.  The epidemiology of venous thromboembolism.

Authors:  Richard H White
Journal:  Circulation       Date:  2003-06-17       Impact factor: 29.690

Review 10.  The treatment and prevention of deep vein thrombosis in the preoperative management of patients who have neurologic diseases.

Authors:  Daniel Farray; Teresa L Carman; Bernardo B Fernandez
Journal:  Neurol Clin       Date:  2004-05       Impact factor: 3.806

View more
  1 in total

1.  Pharmacologic thromboprophylaxis in adult patients undergoing neurosurgical interventions for preventing venous thromboembolism.

Authors:  Juan José Yepes-Nuñez; Anita Rajasekhar; Maryam Rahman; Philipp Dahm; David R Anderson; Luis Enrique Colunga-Lozano; Stephanie Ross; Meha Bhatt; Kelly Estrada Orozco; Federico Popoff; Matthew Ventresca; Angela M Barbara; Sara Balduzzi; Housne Begum; Arnav Agarwal; Wojtek Wiercioch; Robby Nieuwlaat; Gian Paolo Morgano; Holger J Schünemann
Journal:  Blood Adv       Date:  2020-06-23
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.